8.34

1.96% 0.16

Bicycle Therapeutics Plc Adr (BCYC)

Overview News Price History Option Chain Financials Discussions Forecast

Bicycle Therapeutics Plc Adr stock is traded at $8.34, with a volume of 497.93K. It is up +1.96% in the last 24 hours and up +21.22% over the past month. Bicycle Therapeutics PLC is a clinical-stage biopharmaceutical company developing a novel class of medicines which are referred to as Bicycles. The Bicycles are synthetic short peptides constrained to form two loops that stabilize their structural geometry. Its initial internal programs are focused on oncology indications with high unmet medical needs. The company's product candidate, BT1718, is a Bicycle Toxin Conjugate, or BTC. The company has two segments: the United Kingdom and the United States. It derives maximum revenue from United States.

Previous Close:

$8.18

Open:

$8.37

24h Volume:

497.93K

Relative Volume:

1.45

Market Cap:

$644.06M

Revenue:

$36.90M

Net Income/Loss:

$-166.28M

P/E Ratio:

-2.535

EPS:

-3.29

Net Cash Flow:

$-203.53M

1W Performance:

-10.32%

1M Performance:

+21.22%

6M Performance:

-66.59%

1Y Performance:

-64.63%

1-Day Range:

$8.13

$8.60

1-Week Range:

$7.39

$9.31

52-Week Range:

$6.10

$28.67

Bicycle Therapeutics Plc Adr Stock (BCYC) Company Profile

Name

Bicycle Therapeutics Plc Adr

Sector

Healthcare (1153)

Industry

Biotechnology (676)

Phone

011441223261503

Address

BLOCKS A & B, PORTWAY BUILDING, CAMBRIDGE

Employee

305

Twitter

@Bicycle_tx

Next Earnings Date

2024-10-31

Latest SEC Filings

BCYC's Discussions on Twitter

Compare BCYC with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
BCYC Bicycle Therapeutics Plc Adr	8.34	644.06M	36.90M	-166.28M	-203.53M	-3.29
VRTX Vertex Pharmaceuticals Inc	424.99	128.84B	11.10B	-988.90M	-1.26B	-3.92
REGN Regeneron Pharmaceuticals Inc	527.78	65.38B	14.09B	4.50B	2.96B	39.28
ARGX Argen X Se Adr	549.65	39.67B	2.19B	833.04M	-1.28B	12.71
ALNY Alnylam Pharmaceuticals Inc	251.15	33.82B	2.35B	-269.70M	-75.39M	-2.09
ONC Beigene Ltd Adr	231.99	27.60B	3.81B	-644.79M	-669.77M	-6.24

Bicycle Therapeutics Plc Adr Stock (BCYC) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Nov-08-24	Initiated	Stephens	Equal-Weight
Sep-06-24	Initiated	RBC Capital Mkts	Outperform
Aug-07-24	Downgrade	B. Riley Securities	Buy → Neutral
Sep-11-23	Upgrade	B. Riley Securities	Neutral → Buy
Aug-31-22	Initiated	Cowen	Outperform
Jul-28-22	Initiated	Barclays	Overweight
Jul-06-22	Resumed	Canaccord Genuity	Buy
Apr-13-22	Downgrade	B. Riley Securities	Buy → Neutral
Apr-07-22	Resumed	Cantor Fitzgerald	Overweight
Feb-14-22	Initiated	Morgan Stanley	Equal-Weight
Dec-17-21	Initiated	SVB Leerink	Outperform
Dec-09-21	Initiated	Needham	Buy
Sep-30-21	Initiated	B. Riley Securities	Buy
Apr-20-21	Initiated	JMP Securities	Mkt Outperform
Oct-12-20	Initiated	Cantor Fitzgerald	Overweight
Jun-12-20	Initiated	Oppenheimer	Outperform
Apr-17-20	Initiated	H.C. Wainwright	Buy
Nov-14-19	Initiated	ROTH Capital	Buy
Sep-11-19	Upgrade	Goldman	Neutral → Buy
Jun-17-19	Initiated	Canaccord Genuity	Buy
Jun-17-19	Initiated	Goldman	Neutral
Jun-17-19	Initiated	Jefferies	Buy
Jun-17-19	Initiated	Piper Jaffray	Overweight

View All

Bicycle Therapeutics Plc Adr Stock (BCYC) Latest News

May 07, 2025

Market Update: Bicycle Therapeutics Plc ADR (BCYC) Sees Negative Movement, Closing at 7.40 - DWinneX

May 07, 2025

May 01, 2025

Bicycle Therapeutics earnings missed by $0.03, revenue topped estimates - Investing.com South Africa

May 01, 2025

Apr 24, 2025